Equities research analysts expect Tricida Inc (NASDAQ:TCDA) to report ($0.89) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Tricida’s earnings, with the highest EPS estimate coming in at ($0.87) and the lowest estimate coming in at ($0.91). The company is expected to issue its next earnings report on Thursday, February 14th.
On average, analysts expect that Tricida will report full year earnings of ($2.92) per share for the current year, with EPS estimates ranging from ($2.94) to ($2.90). For the next financial year, analysts expect that the business will post earnings of ($3.45) per share, with EPS estimates ranging from ($3.50) to ($3.39). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Tricida.
Tricida (NASDAQ:TCDA) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.19.
Several brokerages recently issued reports on TCDA. Zacks Investment Research downgraded Tricida from a “buy” rating to a “hold” rating in a report on Tuesday. Cowen reiterated a “buy” rating on shares of Tricida in a report on Friday, November 9th.
In other Tricida news, insider Geoffrey M. Parker bought 5,000 shares of the stock in a transaction dated Tuesday, November 13th. The stock was bought at an average cost of $29.72 per share, for a total transaction of $148,600.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Klaus R. Dr Veitinger sold 9,814 shares of the firm’s stock in a transaction dated Wednesday, December 26th. The shares were sold at an average price of $24.97, for a total value of $245,055.58. The disclosure for this sale can be found here. Insiders have sold 21,163 shares of company stock valued at $527,266 over the last 90 days.
Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new stake in shares of Tricida during the second quarter valued at about $299,000. Penserra Capital Management LLC bought a new position in shares of Tricida during the third quarter worth about $452,000. BlackRock Inc. bought a new position in shares of Tricida during the second quarter worth about $9,498,000. Northern Trust Corp bought a new position in shares of Tricida during the second quarter worth about $448,000. Finally, United Services Automobile Association bought a new position in shares of Tricida during the second quarter worth about $568,000. Institutional investors own 68.39% of the company’s stock.
NASDAQ TCDA traded up $0.59 during trading hours on Monday, hitting $21.96. The company had a trading volume of 135,238 shares, compared to its average volume of 223,589. Tricida has a fifty-two week low of $21.08 and a fifty-two week high of $40.10. The company has a current ratio of 12.68, a quick ratio of 12.68 and a debt-to-equity ratio of 0.11.
Tricida Company Profile
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Featured Article: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.